Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced Tuesday, April 3, that after a strategic review, the company will operate two businesses — Minimal Residual Disease (MRD) and Immune Medicine (IM) — internally.
The company will also restructure each business with dedicated resources and separate segment reporting.
Under this structure, Adaptive preserves its strong capital position, which will bridge the MRD business to profitability and support targeted investments in Immune Medicine.
Adaptive Biotechnologies reported the first-quarter fiscal year 2024 preliminary sales of $41 million-$43 million versus ...